Outsourced Drug Discovery: Building Differentiated Service Platforms

The outsourced drug discovery services market is becoming structurally more demanding for Western service providers while also creating clear opportunities for those willing to focus. As we described in our companion Executive Insights, the recovery in biotech funding masks structural shifts in how biopharma allocates R&D dollars: in particular a migration of pipeline growth to China, and a continued shift within Western research from less differentiated activities to specialist expertise.

These shifts are reshaping demand in ways that favour differentiated providers. Sponsors under productivity pressure are concentrating their early-stage spend in workflows where productivity gains are most plausible. In this insight, we describe what success looks like for Western discovery service providers in this market: the value propositions sponsors buy, the credible potential differentiation angles for Western players, and the common pitfalls to avoid.

Sponsors seek solutions to specific scientific problems

The discovery landscape remains highly fragmented, with large diversified CROs competing alongside mid-sized players and specialist boutiques. That fragmentation reflects a fundamental truth about discovery: it is not a single market. It is a value chain spanning target identification, hit identification, lead optimisation, DMPK, toxicology, and translational readouts, served by specialist disciplines including medicinal chemistry, structural biology, computational design, and advanced cellular models. Sponsors source services along this chain with very different decision criteria depending on the workflow, the modality, and the stage of the programme.

In practice, sponsors buy one of a small number of things from a CRO (see Figure 1): scientific depth and access to advanced technology in a chosen area; dry-lab and wet-lab integration that improves decision quality; high-touch scientific service; geographic access and footprint; integrated process speed compressing the gap between discovery and IND readiness; speed at scale on standardised work; and low cost on standardised testing. Underpinning all of these, quality is a table stake. Sponsors are not buying abstract end-to-end capability; they are buying solutions to specific scientific problems within specific workflows, with specific decision-makers approving the spend.

The competitive landscape for these value propositions has shifted. The low cost and speed-at-scale lanes on standardised work are increasingly contested by players in the Chinese CRO ecosystem, which has scaled materially and now competes for more routine work at lower price points. Western providers attempting to compete in these lanes face a structural cost disadvantage. The strong defensible positions for Western providers sit in the other areas.

Winning differentiation angles for Western providers

Several angles look most credible for Western discovery service providers in the reshaped market. The platforms most likely to succeed are those that have selected one or two of these angles and built operations, M&A strategy, and commercial model coherently around them.

1. Scientific depth in specialist modalities
   Deep expertise in areas such as ADC linker chemistry, radioligand discovery, advanced cell models for immunology, or other modality-specific niches is among the most defensible angles because it is hardest to replicate.
    

   It aligns directly with the direction of sponsor demand, as modalities continue to proliferate and few sponsors have the in-house expertise to advance every modality in their pipeline. The scientific complexity of these workflows makes short term replication challenging.

2. Dry-lab and wet-lab integration
   Platforms with genuine investment in areas such as computational design, structural biology, and data infrastructure that demonstrably accelerate wet-lab decisions are increasingly attractive to sponsors under productivity pressure. AI is changing the relative value of different parts of the discovery workflow: it raises the value of data-rich, decision-intensive work, and reduces the relative value of routine experimentation.
    

   Offerings that can credibly demonstrate measurable improvements in hit rates, cycle times, or decision quality through their integrated dry-lab and wet-lab approach will increasingly stand out.

3. Integrated process speed and regulatory readiness
   The ability to deliver IND-ready data packages with traceability, integrated developability assessment, and tight orchestration across discovery, preclinical, and CMC activities addresses a pain point that sponsors find increasingly hard to manage internally as modality complexity rises. Providers that can credibly compress the discovery-to-IND timeline have a defensible position with sponsors who would otherwise need to manage that complexity in-house or across vendors.
4. High-touch scientific partnership
   Some sponsors, such as smaller biotechs, value embedded scientific partnership over throughput. Platforms that build their proposition around the scientific quality of the partnership and the responsiveness of the service can defend premium positioning in specific customer segments, particularly where the alternative requires the sponsor to coordinate multiple vendors at higher transaction cost or to manage IP and confidentiality considerations associated with working with a range of providers.

Across all of these angles, quality has become table stakes rather than a differentiator. Platforms that fail on quality cannot compete. Each angle also requires sustained investment in specific capabilities - scientific talent, computational infrastructure, regulatory expertise, customer relationship management - that build over time and become harder for new entrants to replicate.

Common pitfalls in scaling a discovery service platform

Building around differentiation angles is necessary but not sufficient. We have identified several pitfalls which companies must avoid in parallel.

1. End-to-end overreach
   Platforms often attempt to serve too many customers in too many workflows, without establishing a defensible position in any of them. The useful test is whether the platform can credibly claim to be a top three to five choice in at least one workflow for at least one customer segment.
2. Adjacencies without synergy
   Services that appear adjacent on paper (for example chemistry and biology, in vitro and in vivo, discovery and preclinical) often have different decision-makers, different buying dynamics and demand profiles in practice. Acquiring across them does not automatically create cross-sell, and the integration cost of trying may exceed the realised revenue synergy.
3. Poor integration
   Acquired services may sit under one brand and one P&L while remaining commercially and scientifically separate. The intended customer experience of a coherent platform with shared project management, integrated data, and a single relationship may not materialise. Sponsors notice quickly, and the platform's reputation may suffer.
4. Misaligned go-to-market
   Platform strategies often fail to translate into changes in sales force structure, account ownership, incentives, and messaging. Sales teams continue to sell the services they understand to the customers they know, while the strategic narrative for investors describes a platform that exists primarily in theory rather than in practice.

Positioning for the next phase of growth

The next cycle of value creation in outsourced discovery services will reward platforms that have chosen differentiation angles with conviction and operationalised them across the organisation. Scientific depth, integrated delivery, computational-experimental integration, and high-touch scientific partnership are all credible paths for Western providers, and each connects directly to the demand shifts now reshaping the market. The opportunity is becoming increasingly tangible as the structural tailwinds supporting differentiated providers continue to strengthen. Western providers that choose a defensible area of differentiation and align their operating model behind it will be better positioned to create sustainable value as sponsor priorities continue to evolve.

How L.E.K. Consulting can help

L.E.K. partners with discovery service providers and their investors across the value-creation cycle, from strategic positioning and value proposition design through to M&A screening, commercial and operational due diligence, post-merger integration, and operating model design. We work with both incumbents seeking to sharpen their differentiation in a more contested market and investors evaluating platform investments in the reshaped landscape. To find out more, please contact us.

L.E.K. Consulting is a registered trademark of L.E.K. Consulting. All other products and brands mentioned in this document are properties of their respective owners. © 2026 L.E.K. Consulting